Active Biotech AB, Annual Account for the Operating Year 2001

 | Source: Active Biotech Active Biotech

* SAIK-MS Phase II study to start as planned

* TTS Phase II studies:
- renal cancer study started and go-ahead given for start of pancreatic cancer study

* Candidate drug selected for prostate cancer project

* Patent portfolio further strengthened by US patent approval for prostate cancer project

* Profit after financial items of SEK 34.8 million (SEK -419.4 million) for the full year - in line with forecast

Pièces jointes

Active Biotech AB - Annual Account 2001